Drugs /

h3.3k27m-specific peptide vaccine

Back to Drugs List

Overview

NCI Definition [1]:
A vaccine composed of a peptide derived from histone H3.3 containing the amino acid substitution mutation lysine (Lys) 27-to-methionine (H3.3K27M), with potential immunoactivating and antineoplastic activities. Upon administration of the H3.3K27M-specific peptide vaccine, the immune system may exert a cytotoxic T-lymphocyte (CTL)-mediated immune response against H3.3K27M-expressing tumor cells. The H3.3K27M mutation alters the methylation and acetylation profile of the histone H3 variant H3.3 at Lys 27. Modification of H3.3 at Lys 27 regulates gene expression, and the H3.3K27M mutation occurs in a variety of cancer cell types.

Clinical Trials

View Clinical Trials for h3.3k27m-specific peptide vaccine

H3.3k27m-specific peptide vaccine has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating h3.3k27m-specific peptide vaccine, 1 is phase 1/phase 2 (1 open).

H3F3A K28M and HLA-A*02:01 Positive are the most frequent biomarker inclusion criteria for h3.3k27m-specific peptide vaccine clinical trials.

Diffuse intrinsic pontine glioma, diffuse midline glioma, H3 K27M-mutant, and glioma are the most common diseases being investigated in h3.3k27m-specific peptide vaccine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating H3.3k27m-Specific Peptide Vaccine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating h3.3k27m-specific peptide vaccine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
h3.3k27m peptide vaccine
NCIT ID [1]:
C132684

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.